DOP2021000157A - Composiciones y métodos para tratar, prevenir o revertir la inflamación y los trastornos asociados a la edad - Google Patents
Composiciones y métodos para tratar, prevenir o revertir la inflamación y los trastornos asociados a la edadInfo
- Publication number
- DOP2021000157A DOP2021000157A DO2021000157A DO2021000157A DOP2021000157A DO P2021000157 A DOP2021000157 A DO P2021000157A DO 2021000157 A DO2021000157 A DO 2021000157A DO 2021000157 A DO2021000157 A DO 2021000157A DO P2021000157 A DOP2021000157 A DO P2021000157A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- preventing
- age
- compositions
- treating
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Se describe un método para prevenir, retrasar o revertir la inflamación asociada a la edad, administrando a un paciente que lo necesite una cantidad terapéuticamente eficaz de al menos un inhibidor de la transcriptasa inversa (RTI).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962797109P | 2019-01-25 | 2019-01-25 | |
US201962907251P | 2019-09-27 | 2019-09-27 | |
PCT/US2020/015043 WO2020154656A1 (en) | 2019-01-25 | 2020-01-24 | Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2021000157A true DOP2021000157A (es) | 2021-11-21 |
Family
ID=71735994
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2021000157A DOP2021000157A (es) | 2019-01-25 | 2021-07-22 | Composiciones y métodos para tratar, prevenir o revertir la inflamación y los trastornos asociados a la edad |
Country Status (15)
Country | Link |
---|---|
US (1) | US11793814B2 (es) |
EP (1) | EP3914604A4 (es) |
JP (1) | JP2022521454A (es) |
KR (1) | KR20210137434A (es) |
CN (1) | CN113631563A (es) |
AU (1) | AU2020211600A1 (es) |
BR (1) | BR112021014576A2 (es) |
CA (1) | CA3125991A1 (es) |
CL (1) | CL2021001951A1 (es) |
DO (1) | DOP2021000157A (es) |
IL (1) | IL285072A (es) |
MX (1) | MX2021008751A (es) |
SG (1) | SG11202107145SA (es) |
UA (1) | UA128041C2 (es) |
WO (1) | WO2020154656A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3927710A4 (en) * | 2019-03-08 | 2022-12-21 | University of Virginia Patent Foundation | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF ALZHEIMER'S DISEASE |
WO2021102423A1 (en) * | 2019-11-22 | 2021-05-27 | Brown University | Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders |
TW202228724A (zh) * | 2020-09-23 | 2022-08-01 | 美商昂克萊亞製藥公司 | 以反轉錄酶抑制劑治療癌症之方法 |
AU2021347247A1 (en) * | 2020-09-23 | 2023-06-08 | Transposon Therapeutics, Inc. | Line-1 inhibitors to treat disease |
AU2022237405A1 (en) * | 2021-03-15 | 2023-11-02 | Transposon Therapeutics, Inc. | Line-1 inhibitors to treat cns and systemic diseases |
CN113134003A (zh) * | 2021-05-11 | 2021-07-20 | 山东第一医科大学附属省立医院(山东省立医院) | 拉米夫定在制备治疗阿尔茨海默症药物中的应用 |
JP2024520132A (ja) * | 2021-06-04 | 2024-05-21 | トランスポゾン セラピューティクス インコーポレイテッド | 向知性薬としてのline-1阻害剤 |
WO2022264966A1 (ja) * | 2021-06-14 | 2022-12-22 | 国立大学法人九州大学 | 発達障害および精神疾患の処置および予防 |
WO2023019351A1 (en) * | 2021-08-16 | 2023-02-23 | University Health Network | Methods and compositions for treating alpha-synuclein-mediated neurodegeneration |
GB202115281D0 (en) * | 2021-10-23 | 2021-12-08 | Queens Univ Of Belfast | Cardiovascular disease treament or prevention |
WO2023105283A1 (en) * | 2021-12-08 | 2023-06-15 | Fundacio Privada Institut De Recerca De La Sida - Caixa | Nucleoside reverse transcriptase inhibitors for use in down syndrome and alzheimer`s disease therapy |
WO2023164472A1 (en) * | 2022-02-22 | 2023-08-31 | Rome Therapeutics, Inc. | Methods of treating medical conditions using censavudine or a related compound |
WO2023178128A1 (en) * | 2022-03-15 | 2023-09-21 | Rome Therapeutics, Inc. | Methods of treating medical conditions using islatravir or a related compound |
CN114958852A (zh) * | 2022-06-09 | 2022-08-30 | 赛业(苏州)生物科技有限公司 | 一种Ifnar1基因敲除小鼠动物模型的构建方法及其应用 |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
US6110973A (en) | 1998-01-29 | 2000-08-29 | Sepracor | Methods for treating obesity and weight gain using optically pure (-)-bupropion |
BR0011521B8 (pt) | 1999-05-12 | 2021-05-25 | Yamasa Corp | compostos nucleósidos de purina de 4 -c-etinila |
AU2002248213A1 (en) * | 2000-12-19 | 2002-08-19 | Hospital For Special Surgery | Markers for disease susceptibility and targets for therapy |
US20050113324A1 (en) * | 2003-01-15 | 2005-05-26 | Bondarev Igor E. | Modulation of line-1 reverse transcriptase |
US20060160087A1 (en) | 2003-01-31 | 2006-07-20 | Mcgrath Michael | Monitoring and treatment of amyotrophic lateral sclerosis |
CA2514466C (en) | 2003-02-19 | 2015-05-26 | Yale University | Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections |
WO2004090097A2 (en) | 2003-04-03 | 2004-10-21 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human p2x7 splice variant, hbmyp2x7v |
US20060020042A1 (en) * | 2004-01-05 | 2006-01-26 | Forest Laboratories, Inc. | Memantine for the treatment of mild and mild to moderate Alzheimer's disease |
CA2502109C (en) | 2004-03-24 | 2010-02-23 | Yamasa Corporation | 4'-c-substituted-2-haloadenosine derivative |
US8173623B2 (en) | 2006-03-29 | 2012-05-08 | Gilead Sciences, Inc. | Process for preparation of HIV protease inhibitors |
WO2008054808A2 (en) * | 2006-10-31 | 2008-05-08 | Achillion Pharmaceuticals, Inc. | Elvucitabine pharmaceutical compositions |
KR20100041798A (ko) | 2007-06-29 | 2010-04-22 | 한국화학연구원 | 신규 hiv 역전사효소 억제제 |
CN101784532B (zh) | 2007-06-29 | 2014-10-22 | 韩国化学研究院 | Hiv逆转录酶抑制剂 |
US9051288B2 (en) | 2007-12-27 | 2015-06-09 | Oncolys Biopharma, Inc. | Method for producing 4′-ethynyl d4T |
US8445669B2 (en) | 2008-04-10 | 2013-05-21 | Hamari Chemicals, Ltd. | Production process of ethynylthymidine compounds from 5-methyluridine as a starting material |
WO2009126293A2 (en) | 2008-04-11 | 2009-10-15 | Yale University | Potent chimeric nrti-nnrti bifunctional inhibitors of hiv-1 reverse transcriptase |
DE102008029460A1 (de) | 2008-06-20 | 2009-12-31 | Otkrytoe Aktsionernoe Obschestvo Zavod Ekologicheskoy Tekhniki I Ekopitaniya 'diod' | Taxifolinderivate zur Prophylaxe und Behandlung von neurologischen und psychiatrischen Störungen des zentralen Nervensystems |
JP5924479B2 (ja) | 2010-02-15 | 2016-05-25 | 日産化学工業株式会社 | β−ジヒドロフラン誘導化合物、β−ジヒドロフラン誘導化合物またはβ−テトラヒドロフラン誘導化合物の製造方法、並びにβ−グリコシド化合物の製造方法 |
WO2012068630A1 (en) * | 2010-11-26 | 2012-05-31 | The University Of Melbourne | Methods and compositions comprising antagonists of type 1 interferon-mediated signalling for reducing a neuroinflammatory response in the central nervous system following a stroke |
DK2665471T3 (en) | 2011-01-19 | 2018-03-19 | Pathologica Llc | ORAL PHARMACEUTICAL DOSAGE FORMS WITH MANAGED RELEASE COMPREHENSIVE MGBG |
AR087274A1 (es) * | 2011-07-22 | 2014-03-12 | Actelion Pharmaceuticals Ltd | Derivados de amidas heterociclicas como antagonistas de receptores p2x7 |
WO2013057469A1 (en) | 2011-10-20 | 2013-04-25 | Cipla Limited | Pharmaceutical antiretroviral compositions |
IN2014MN01907A (es) | 2012-03-05 | 2015-07-10 | Cipla Ltd | |
CN104379571A (zh) | 2012-05-23 | 2015-02-25 | 百时美施贵宝公司 | 用于制备festinavir的硫亚胺和亚砜方法 |
WO2014039696A2 (en) | 2012-09-05 | 2014-03-13 | Cold Spring Harbor Laboratory | Transposable elements, tdp-43, and neurodegenerative disorders |
WO2014145613A2 (en) | 2013-03-15 | 2014-09-18 | Cold Spring Harbor Laboratory | Transposon activation during aging and neuronal decline |
IN2013MU01749A (es) | 2013-05-15 | 2015-06-26 | Cipla Ltd | |
US20160130260A1 (en) | 2013-06-13 | 2016-05-12 | Bristol-Myers Squibb Company | Tert-butyl sulphoxide method for producing festinavir |
US9549942B2 (en) | 2013-07-15 | 2017-01-24 | Research & Business Foundation Sungkyunkwan University | Composition for preventing or treating degenerative brain diseases including compound downregulating expression of BACE1 proteins |
CN106163557B (zh) * | 2014-01-28 | 2020-07-14 | 巴克老龄化研究所 | 用于杀死衰老细胞和用于治疗衰老相关疾病和病症的方法和组合物 |
WO2015143712A1 (en) | 2014-03-28 | 2015-10-01 | Merck Sharp & Dohme Corp. | 4'-substituted nucleoside reverse transcriptase inhibitors |
EP2965760A1 (en) | 2014-07-09 | 2016-01-13 | Université de Montpellier | Combination of antiretroviral agents for use in the prevention or treatment of chronic inflammatory diseases |
FR3027804A1 (fr) * | 2014-10-31 | 2016-05-06 | Centre Nat Rech Scient | Utilisation d'un inhibiteur de transcriptase inverse dans la prevention et le traitement des maladies degeneratives |
US10059940B2 (en) | 2015-01-27 | 2018-08-28 | Minghong Zhong | Chemically ligated RNAs for CRISPR/Cas9-lgRNA complexes as antiviral therapeutic agents |
PL3261644T3 (pl) | 2015-02-26 | 2021-10-25 | University Of Kentucky Research Foundation | Kompozycje i sposoby leczenia degradacji siatkówki |
WO2016149561A1 (en) | 2015-03-17 | 2016-09-22 | Oak Crest Institute Of Science | Subdermal implants for the sustained delivery of water-soluble drugs |
WO2016191481A1 (en) | 2015-05-28 | 2016-12-01 | Immunomedics, Inc. | T20 constructs for anti-hiv (human immunodeficiency virus) therapy and/or vaccines |
KR20180014778A (ko) | 2015-06-03 | 2018-02-09 | 트리아스텍 인코포레이티드 | 제형 및 이의 용도 |
US10765679B2 (en) | 2015-07-04 | 2020-09-08 | Emory University | Use of TREM-1 inhibitors for treatment, elimination and eradication of HIV-1 infection |
TN2018000048A1 (en) | 2015-08-10 | 2019-07-08 | Merck Sharp & Dohme | Antiviral beta-amino acid ester phosphodiamide compounds |
CA2998646C (en) | 2015-09-23 | 2021-05-18 | Merck Sharp & Dohme Corp. | 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof |
US20180360959A1 (en) * | 2015-09-25 | 2018-12-20 | Universität Duisburg-Essen | Agents inhibiting kallikrein-8 for use in the prevention or treatment of alzheimer's disease |
EP3355924A1 (en) | 2015-09-29 | 2018-08-08 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Methods of treating and preventing amyotrophic lateral sclerosis |
WO2017100108A1 (en) | 2015-12-10 | 2017-06-15 | Merck Sharp & Dohme Corp. | Antiviral phosphodiamide prodrugs of tenofovir |
EP3390413B1 (en) | 2015-12-15 | 2020-08-19 | Merck Sharp & Dohme Corp. | Antiviral oxime phosphoramide compounds |
JOP20170038B1 (ar) | 2016-02-12 | 2021-08-17 | Merck Sharp & Dohme | مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه |
AU2017218800B2 (en) | 2016-02-12 | 2022-09-22 | Cipla Limited | Pharmaceutical compositions comprising an anti-retroviral drug and a pharmacokinetic enhancer |
EP3426642A4 (en) | 2016-03-09 | 2019-10-09 | Janssen BioPharma, Inc. | ACYCLIC ANTIVIRALS |
KR102272235B1 (ko) | 2016-05-12 | 2021-07-01 | 머크 샤프 앤드 돔 코포레이션 | 항바이러스제의 전달을 위한 약물 전달 시스템 |
WO2017222903A1 (en) | 2016-06-20 | 2017-12-28 | Merck Sharp & Dohme Corp. | Drug delivery system for the delivery of antiviral agents |
PE20190910A1 (es) | 2016-08-19 | 2019-06-26 | Gilead Sciences Inc | Compuestos terapeuticos utiles para el tratamiento profilactico o terapeutico de una infeccion por el virus del vih |
EP3503895B1 (en) | 2016-08-25 | 2021-09-15 | Merck Sharp & Dohme Corp. | Antiviral prodrugs of tenofovir |
US10266558B2 (en) | 2016-10-07 | 2019-04-23 | Alexandre Vasilievich Ivachtchenko | Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof |
EP3532069A4 (en) | 2016-10-26 | 2020-05-13 | Merck Sharp & Dohme Corp. | ARYL-AMIDE PHOSPHODIAMIDE COMPOUNDS ANTIVIRALS |
US20180153859A1 (en) | 2016-12-02 | 2018-06-07 | T3D Therapeutics, Inc. | Methods of treating or preventing cognitive impairment using indane acetic acid derivatives based on apoe4 genotype |
JOP20190130A1 (ar) | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
MX2019007262A (es) | 2016-12-22 | 2019-09-05 | Merck Sharp & Dohme | Compuestos antivirales de bencilamina fosfodiamida. |
MX2019007585A (es) | 2016-12-22 | 2019-09-09 | Merck Sharp & Dohme | Profarmacos de ester alifatico antiviricos de tenofovir. |
WO2018191093A1 (en) | 2017-04-10 | 2018-10-18 | Merck Sharp & Dohme Corp. | Drug delivery system for the delivery of antiviral agents |
TW201906834A (zh) | 2017-05-02 | 2019-02-16 | 英商Viiv醫療保健英國(No.5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
WO2019009793A1 (en) | 2017-07-04 | 2019-01-10 | Cavidi Ab | METHOD FOR ASSESSING THE SENSITIVITY OF A VIRUS TO TREATMENT BY MEASURING ENZYMA ACTIVITY AND SYSTEM THEREOF |
US20200138845A1 (en) | 2017-07-18 | 2020-05-07 | Viiv Healthcare Company | Combination Drug Therapy |
AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
AR112413A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas sólidas de un inhibidor de la cápside del vih |
US11040975B2 (en) | 2017-12-08 | 2021-06-22 | Merck Sharp & Dohme Corp. | Carbocyclic nucleoside reverse transcriptase inhibitors |
US20190185508A1 (en) | 2017-12-15 | 2019-06-20 | Merck Sharp & Dohme Corp. | Deuterated nucleoside reverse transcriptase inhibitors |
MX2020006864A (es) | 2017-12-27 | 2020-11-11 | Univ Emory | Modalidades combinadas para inhibidores de nucleosidos y/o nadph oxidasa (nox) como agentes antivirales especificos de mieloides. |
US11839623B2 (en) | 2018-01-12 | 2023-12-12 | Board Of Regents Of The University Of Nebraska | Antiviral prodrugs and formulations thereof |
US20200407393A1 (en) | 2018-03-07 | 2020-12-31 | Glaxosmithkline Intellectual Property (No. 2) Limited | Medical Use |
US20210267995A1 (en) | 2018-06-20 | 2021-09-02 | Sanford Burnham Prebys Medical Discovery Institute | Anti-retroviral therapies and reverse transcriptase inhibitors for treatment of alzheimer's disease |
CN109893536B (zh) | 2018-07-02 | 2021-04-27 | 河南真实生物科技有限公司 | 4’-取代核苷的晶型、制备和应用 |
EP3820473A4 (en) | 2018-07-09 | 2022-05-11 | Merck Sharp & Dohme Corp. | ENZYMATIC SYNTHESIS OF 4'-ETHINYL NUCLEOSIDE ANALOGUES |
SG11202012111UA (en) | 2018-07-09 | 2021-01-28 | Codexis Inc | Engineered purine nucleoside phosphorylase variant enzymes |
US11274286B2 (en) | 2018-07-09 | 2022-03-15 | Codexis, Inc. | Engineered deoxyribose-phosphate aldolases |
WO2020018459A1 (en) | 2018-07-16 | 2020-01-23 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of hiv |
EP3823632A4 (en) | 2018-07-17 | 2022-04-20 | Merck Sharp & Dohme Corp. | COMBINATION OF HIV DRUGS TO INCREASE THE BARRIER AGAINST RESISTANCE |
EP3823629A4 (en) | 2018-07-19 | 2022-05-04 | Merck Sharp & Dohme Corp. | PHOSPHINAMIDE PRODRUGS OF TENOFOVIR |
US20220117993A1 (en) | 2018-08-09 | 2022-04-21 | Glaxosmithkline Intellectual Property (No. 2) Limited | Compounds Useful in HIV Therapy |
JP2021536444A (ja) | 2018-08-30 | 2021-12-27 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | Hiv療法に有用な化合物 |
WO2020053811A1 (en) | 2018-09-14 | 2020-03-19 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
JP7433303B2 (ja) | 2018-09-20 | 2024-02-19 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
CA3114239A1 (en) | 2018-10-16 | 2020-04-23 | Research Triangle Institute | Subcutaneous biodegradable reservoir device |
TWI721624B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
TWI721623B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
MX2021007544A (es) | 2018-12-20 | 2021-08-11 | Merck Sharp & Dohme Llc | Nuevas formas cristalinas de un compuesto inhibidor de la translocacion de la transcriptasa inversa de nucleosidos. |
MX2021007525A (es) | 2018-12-21 | 2021-09-21 | Univ Liverpool | Terapias con nrti. |
EP3927710A4 (en) * | 2019-03-08 | 2022-12-21 | University of Virginia Patent Foundation | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF ALZHEIMER'S DISEASE |
CA3149147A1 (en) * | 2019-08-23 | 2021-03-04 | Jayakrishna Ambati | Ddx17 and nlrc4 targeting for inflammatory diseases |
-
2020
- 2020-01-24 UA UAA202104068A patent/UA128041C2/uk unknown
- 2020-01-24 WO PCT/US2020/015043 patent/WO2020154656A1/en active Application Filing
- 2020-01-24 EP EP20744317.7A patent/EP3914604A4/en active Pending
- 2020-01-24 BR BR112021014576-1A patent/BR112021014576A2/pt unknown
- 2020-01-24 AU AU2020211600A patent/AU2020211600A1/en active Pending
- 2020-01-24 CA CA3125991A patent/CA3125991A1/en active Pending
- 2020-01-24 MX MX2021008751A patent/MX2021008751A/es unknown
- 2020-01-24 SG SG11202107145SA patent/SG11202107145SA/en unknown
- 2020-01-24 KR KR1020217023887A patent/KR20210137434A/ko unknown
- 2020-01-24 JP JP2021543271A patent/JP2022521454A/ja active Pending
- 2020-01-24 CN CN202080010653.1A patent/CN113631563A/zh active Pending
- 2020-07-21 US US16/934,826 patent/US11793814B2/en active Active
-
2021
- 2021-07-22 IL IL285072A patent/IL285072A/en unknown
- 2021-07-22 DO DO2021000157A patent/DOP2021000157A/es unknown
- 2021-07-23 CL CL2021001951A patent/CL2021001951A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
IL285072A (en) | 2021-09-30 |
BR112021014576A2 (pt) | 2021-10-05 |
JP2022521454A (ja) | 2022-04-08 |
CN113631563A (zh) | 2021-11-09 |
US20210106586A1 (en) | 2021-04-15 |
WO2020154656A1 (en) | 2020-07-30 |
EP3914604A1 (en) | 2021-12-01 |
KR20210137434A (ko) | 2021-11-17 |
UA128041C2 (uk) | 2024-03-20 |
MX2021008751A (es) | 2021-11-12 |
CL2021001951A1 (es) | 2022-04-08 |
SG11202107145SA (en) | 2021-08-30 |
CA3125991A1 (en) | 2020-07-30 |
AU2020211600A1 (en) | 2021-07-22 |
EP3914604A4 (en) | 2022-10-19 |
US11793814B2 (en) | 2023-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2021000157A (es) | Composiciones y métodos para tratar, prevenir o revertir la inflamación y los trastornos asociados a la edad | |
EA202190630A1 (ru) | Способы комбинированной терапии | |
CL2021002100A1 (es) | Combinación farmacéutica que comprende tno155 y un inhibidor de pd–1. | |
CO2021015318A2 (es) | Compuestos y métodos para el tratamiento de covid-19 | |
CL2021002099A1 (es) | Combinación farmacéutica que comprende tno155 y ribociclib. | |
BR112016020199A8 (pt) | composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
BR112016026560A2 (pt) | Método para tratar uma complicação de uma doença hepática crônica, método para tratar hipertensão portal, método para inibir uma cascata de sinalização de tnf-a e de a-fas; composição farmacêutica, kit, método de tratamento, método para tratar uma afecção | |
CL2022000194A1 (es) | Uso para tratar la enfermedad de hemorragia alveolar difusa asociada con trasplante de células madre hematopoyéticas (divisional de la solicitud no. 202000384) | |
CL2023001952A1 (es) | Inhibidores de alk2 para el tratamiento de la anemia (divisional). | |
EA202190776A1 (ru) | Комбинация маломолекулярных ингибиторов cd-47 с другими противораковыми агентами | |
EA202192528A1 (ru) | Комбинация ингибиторов pd-1 и ингибиторов lag-3 для повышения эффективности при лечении рака | |
CL2017001913A1 (es) | Composición tópica curativa | |
CO2021015622A2 (es) | Terapias de combinación que comprenden inhibidores de apremilast y tyk2 | |
BR112023000687A2 (pt) | Métodos e combinações de inibidores de kat6 para o tratamento de câncer | |
BR112023015210A2 (pt) | Inibidores de cdk2 e métodos de uso dos mesmos | |
BR112022018115A2 (pt) | Inibidor de cxcr4 para o tratamento de síndrome de desconforto respiratório agudo e infecções virais | |
BR112023019211A2 (pt) | Inibidores de inflamassoma nlrp3 | |
CL2023002746A1 (es) | Inhibidores de la línea 1 para tratar enfermedades del snc y sistémicas | |
CO2022000426A2 (es) | Inhibidores de calicreína plasmática | |
CL2022001102A1 (es) | Métodos para el tratamiento de trastornos depresivos. | |
MX2022013867A (es) | Combinacion farmaceutica que comprende tno155 y nazartinib. | |
CO2023006808A2 (es) | Regímenes para el tratamiento de los trastornos de la pérdida de cabello con inhibidores de jak deuterados | |
CL2022003507A1 (es) | Composición y método para tratar el dolor crónico | |
MX2022004806A (es) | Metodos y composiciones para tratar la anemia drepanocitica con un inhibidor de la ferroportina (vit-2763). | |
MX2022011725A (es) | Metodos para tratar una lesion pulmonar con inhibidores de cgrp. |